Cargando…
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective
PURPOSE: For patients with cancer of unknown primary (CUP), treatment options are limited. Precision oncology, the interplay of comprehensive genomic profiling (CGP) and targeted therapies, aims to offer additional treatment options to patients with advanced and hard-to-treat cancers. We aimed to hi...
Autores principales: | Weiss, L., Heinrich, K., Zhang, D., Dorman, K., Rühlmann, K., Hasselmann, K., Klauschen, F., Kumbrink, J., Jung, A., Rudelius, M., Mock, A., Ormanns, Steffen, Kunz, W. G., Roessler, D., Beyer, G., Corradini, S., Heinzerling, L., Haas, M., von Bergwelt-Baildon, M., Boeck, S., Heinemann, V., Westphalen, C. B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374717/ https://www.ncbi.nlm.nih.gov/pubmed/37062035 http://dx.doi.org/10.1007/s00432-023-04741-y |
Ejemplares similares
-
A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich
por: Zhang, Danmei, et al.
Publicado: (2023) -
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich(LMU) Molecular Tumor Board
por: Dorman, Klara, et al.
Publicado: (2023) -
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2020) -
Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021) -
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Sams, L., et al.
Publicado: (2021)